Molecular test Genotype®MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis

Luis Asencios; Marco Galarza; Neyda Quispe; Lucy Vásquez; Elena Leo; Eddy Valencia; Juan Ramírez; Margoth Acurio; Rosario Salazar; Alberto Mendoza-Ticona; Omar Cáceres

doi:10.1590/S1726-46342012000100014

Molecular test Genotype®MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis

Luis Asencios, Marco Galarza, Neyda Quispe, Lucy Vásquez, Elena Leo, Eddy Valencia, Juan Ramírez, Margoth Acurio, Rosario Salazar, Alberto Mendoza-Ticona, Omar Cáceres

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

The Genotype®MTBDRplus molecular test is a method that allows identifcation of the most frequent mutations associated with resistance to major frst-line antituberculosis drugs, Isoniazid (INH) and Rifampicin (RfP). The aim of this study was to evaluate the performance of the molecular test with culture and smear- positive sputum samples. We evaluated 95 cultures and 100 sputum samples with resistance profles previously determined by the reference method "Agar Plate Proportions" (APP). The molecular test from cultures showed a sensitivity of 100%, 97,5% and 96,97% for RIf, INH and MDR respectively while from sputums the sensitivity was 95,65%, 96,77% and 95,24% for RIf, INH and MDR respectively. We conclude that the molecular test Genotype®MTBDRplus is a very useful tool to detect resistance to isoniazid and rifampicin simultaneously (MDR-TB) in up to 72 hours from sputum samples or cultures.

Translated title of the contribution	Prueba molecular Genotype®MTBDRplus, una alternativa para la detección rápida de tuberculosis multidrogorresistente
Original language	English (US)
Pages (from-to)	92-98
Number of pages	7
Journal	Revista Peruana de Medicina Experimental y Salud Publica
Volume	29
Issue number	1
DOIs	https://doi.org/10.1590/S1726-46342012000100014
State	Published - Mar 2012
Externally published	Yes

All Science Journal Classification (ASJC) codes

Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1590/S1726-46342012000100014

Cite this

Asencios, L., Galarza, M., Quispe, N., Vásquez, L., Leo, E., Valencia, E., Ramírez, J., Acurio, M., Salazar, R., Mendoza-Ticona, A., & Cáceres, O. (2012). Molecular test Genotype®MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis. Revista Peruana de Medicina Experimental y Salud Publica, 29(1), 92-98. https://doi.org/10.1590/S1726-46342012000100014

@article{d3fe2bf6c29248259899632c27889ba4,

title = "Molecular test Genotype{\textregistered}MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis",

abstract = "The Genotype{\textregistered}MTBDRplus molecular test is a method that allows identifcation of the most frequent mutations associated with resistance to major frst-line antituberculosis drugs, Isoniazid (INH) and Rifampicin (RfP). The aim of this study was to evaluate the performance of the molecular test with culture and smear- positive sputum samples. We evaluated 95 cultures and 100 sputum samples with resistance profles previously determined by the reference method {"}Agar Plate Proportions{"} (APP). The molecular test from cultures showed a sensitivity of 100%, 97,5% and 96,97% for RIf, INH and MDR respectively while from sputums the sensitivity was 95,65%, 96,77% and 95,24% for RIf, INH and MDR respectively. We conclude that the molecular test Genotype{\textregistered}MTBDRplus is a very useful tool to detect resistance to isoniazid and rifampicin simultaneously (MDR-TB) in up to 72 hours from sputum samples or cultures.",

author = "Luis Asencios and Marco Galarza and Neyda Quispe and Lucy V{\'a}squez and Elena Leo and Eddy Valencia and Juan Ram{\'i}rez and Margoth Acurio and Rosario Salazar and Alberto Mendoza-Ticona and Omar C{\'a}ceres",

year = "2012",

month = mar,

doi = "10.1590/S1726-46342012000100014",

language = "English (US)",

volume = "29",

pages = "92--98",

journal = "Revista Peruana de Medicina Experimental y Salud Publica",

issn = "1726-4634",

publisher = "Instituto Nacional de Salud",

number = "1",

}

Asencios, L, Galarza, M, Quispe, N, Vásquez, L, Leo, E, Valencia, E, Ramírez, J, Acurio, M, Salazar, R, Mendoza-Ticona, A & Cáceres, O 2012, 'Molecular test Genotype®MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis', Revista Peruana de Medicina Experimental y Salud Publica, vol. 29, no. 1, pp. 92-98. https://doi.org/10.1590/S1726-46342012000100014

TY - JOUR

T1 - Molecular test Genotype®MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis

AU - Asencios, Luis

AU - Galarza, Marco

AU - Quispe, Neyda

AU - Vásquez, Lucy

AU - Leo, Elena

AU - Valencia, Eddy

AU - Ramírez, Juan

AU - Acurio, Margoth

AU - Salazar, Rosario

AU - Mendoza-Ticona, Alberto

AU - Cáceres, Omar

PY - 2012/3

Y1 - 2012/3

N2 - The Genotype®MTBDRplus molecular test is a method that allows identifcation of the most frequent mutations associated with resistance to major frst-line antituberculosis drugs, Isoniazid (INH) and Rifampicin (RfP). The aim of this study was to evaluate the performance of the molecular test with culture and smear- positive sputum samples. We evaluated 95 cultures and 100 sputum samples with resistance profles previously determined by the reference method "Agar Plate Proportions" (APP). The molecular test from cultures showed a sensitivity of 100%, 97,5% and 96,97% for RIf, INH and MDR respectively while from sputums the sensitivity was 95,65%, 96,77% and 95,24% for RIf, INH and MDR respectively. We conclude that the molecular test Genotype®MTBDRplus is a very useful tool to detect resistance to isoniazid and rifampicin simultaneously (MDR-TB) in up to 72 hours from sputum samples or cultures.

AB - The Genotype®MTBDRplus molecular test is a method that allows identifcation of the most frequent mutations associated with resistance to major frst-line antituberculosis drugs, Isoniazid (INH) and Rifampicin (RfP). The aim of this study was to evaluate the performance of the molecular test with culture and smear- positive sputum samples. We evaluated 95 cultures and 100 sputum samples with resistance profles previously determined by the reference method "Agar Plate Proportions" (APP). The molecular test from cultures showed a sensitivity of 100%, 97,5% and 96,97% for RIf, INH and MDR respectively while from sputums the sensitivity was 95,65%, 96,77% and 95,24% for RIf, INH and MDR respectively. We conclude that the molecular test Genotype®MTBDRplus is a very useful tool to detect resistance to isoniazid and rifampicin simultaneously (MDR-TB) in up to 72 hours from sputum samples or cultures.

UR - http://www.scopus.com/inward/record.url?scp=84859992633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859992633&partnerID=8YFLogxK

U2 - 10.1590/S1726-46342012000100014

DO - 10.1590/S1726-46342012000100014

M3 - Article

AN - SCOPUS:84859992633

SN - 1726-4634

VL - 29

SP - 92

EP - 98

JO - Revista Peruana de Medicina Experimental y Salud Publica

JF - Revista Peruana de Medicina Experimental y Salud Publica

IS - 1

ER -

Molecular test Genotype®MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this